生物技术公司Arrowhead Pharmaceuticals（ARWR）周二盘前股价大涨10.02%，主要受到该公司最新季度财报超出市场预期的推动。
根据公司公布的财报，截至3月31日的季度中，Arrowhead Pharmaceuticals实现调整后每股收益2.75美元，远超分析师平均预期的每股亏损0.20美元。公司营收达到5.43亿美元，同样大幅超过分析师预期的2991万美元。这一出色的业绩表现令投资者感到惊喜，推动公司股价在盘前交易中显著上涨。
值得注意的是，尽管公司业绩表现亮眼，加拿大皇家银行仍将Arrowhead Pharmaceuticals的目标价从42美元下调至40美元。然而，考虑到公司的强劲财务表现，这一小幅下调似乎并未影响投资者的积极情绪。目前，华尔街分析师对该公司股票的平均评级仍为"买入"，12个月目标价中位数为41.00美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.